We compared the efficacy and safety of gemcitabine, cisplatin, prednisone and thalidomide (GDPT) with standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) for patients with newly diagnosed peripheral T-cell lymphoma (PTCL) in a prospective randomized controlled and open-label clinical trial. Between July 2010 and June 2016, 103 patients were randomly allocated into two groups, of whom 52 were treated with GDPT therapy and 51 with CHOP therapy. The 2-year progression-free survival (PFS) and overall survival (OS) rates were better in the GDPT group than in the CHOP group (57% vs. 35% for 2-year PFS, P = 0Á0035; 71% vs 50% for 2-year OS, P = 0Á0001). The complete remission rate (CRR) and the overall response rate (ORR) in the GDPT group were higher than in the CHOP group (52% vs. 33%, P = 0Á044 for CRR; 67% vs. 49%, P = 0Á046 for ORR). Haemocytopenia was the predominant adverse effect, and acute toxicity was moderate, tolerable and well managed in both arms. mRNA expression of ERCC1, RRM1, TUBB3 and TOP2A genes varied among patients but the difference did not reach statistical significance, mainly due to the relatively small sample size. The precise characters of these biomarkers remain to be identified. In conclusion, GDPT is a promising new regimen as potential first-line therapy against PTCL. This study was registered at www.clinicaltrials.gov as #NCT01664975.
Lymphoma is a serious threat to the health of humans and has an increasing prevalence rate. The peripheral T-cell lymphomas (PTCL), a subgroup of lymphoma, comprise a spectrum of heterogeneity with distinct phenotypes, different clinical presentations and aggressive biological courses. They are derived from mature T-cells and can be classified into thymic-based and post-thymic diseases. The most common subtypes include PTCL-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL) (Reiser et al, 2002; Savage et al, 2004 Savage et al, , 2011 Vose et al, 2008; Dunleavy et al, 2010; Foss et al, 2011; Moskowitz et al, 2012; Shustov, 2013) . PTCL are relatively rare in western countries, constituting approximately 10-15% of all non-Hodgkin lymphomas (NHL) in North America, but are more commonly found in Eastern Asia, where they comprise 20-30% of cases, with morbidity and mortality rates increasing worldwide (Reiser et al, 2002; Vose et al, 2008; Dunleavy et al, 2010) . The pathogenesis of PTCL has not been fully elucidated at the molecular level. There is no consensus about the optimal therapy for PTCL; the traditional CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) has previously been used as the reference front-line chemotherapy, in accordance with National Comprehensive Cancer Network guidelines, which have been mainly developed from therapeutic paradigms of B cell NHL (Abouyabis et al, 2011) . However, the outcome is poor with regard to remission and survival, with a longterm survival rate of only 10-30%. This dismal prognosis can, to a large extent, be explained by chemoresistance and a lack of biomarkers for targeted drugs (Gisselbrecht et al, 1998; Schmitz et al, 2010; Mak et al, 2013) . The evidence for potential improvement after high-dose chemotherapy followed by autologous stem cell transplantation for eligible patients with PTCL who are responsive to chemotherapy is still unclear, and 5-year progression-free survival (PFS) and overall survival (OS) rates have been reported to be as low as 24% and 33%, respectively (Rodriguez et al, 2001; Mounier et al, 2004; Smith et al, 2013) . As a consequence, the overall prognosis of PTCL remains poor, and rapid relapses can occur. Given these unsatisfactory outcomes, it is imperative to develop more effective and less toxic innovative therapeutic regimens. Several studies have demonstrated that gemcitabine has potent activity against PTCL and it is now widely used, not only as a single-agent but also in combination chemotherapy, especially for relapsed/refractory PTCL, with an overall response rate (ORR) of 50-75% (Zinzani et al, 1998; Howman & Prince, 2011; Dong et al, 2013; Coiffier et al, 2014) . The efficacy of a multi-drug therapeutic schedule including gemcitabine, cisplatin and dexamethasone/ prednisone in the treatment of PTCL has been reported in several studies, and is now considered to be the therapy of choice for relapsed/refractory patients (Emmanouilides et al, 2004; Arkenau et al, 2007; Yao et al, 2013) . As far as we are aware, there have been no published reports about the addition of thalidomide to this combination for patients with newly diagnosed PTCL. Thalidomide has been shown to exert antitumour effects through the properties of immunomodulation, inhibiting angiogenesis, promoting apoptosis and suppressing inflammation. It can also alleviate the digestive tract toxicity of chemotherapy. Accordingly, we devised an alternative therapeutic regimen, GDPT (gemcitabine, cisplatin, prednisone, thalidomide), and performed a prospective randomized controlled clinical trial to investigate the efficacy and safety of this treatment compared with CHOP in patients with newly diagnosed PTCL.
Previous studies have shown that the clinical activity of chemotherapy agents are relevant to the expression of some interesting genes. In tumour tissues, the low expression of ERCC1 was reported to be highly sensitive to cisplatin and a lower expression of RRM1 was related to a better gemcitabine clinical outcome (Ulker et al, 2015) . Similarly, the expression of TUBB3 was reported to have negative correlation with the curative effect of paclitaxel and vinca alkaloids (Ferlini et al, 2007) . However, patients with a low expression of TOP2A were reported to have a high resistance to anthracycline (Bartlett et al, 2015) . Nevertheless, there are few studies of these genes in PTCL. We detected the expression of these four genes in order to find the connection between the expression level and the prognosis, and to determine appropriate antineoplastic protocols with the aim of obtaining the maximum benefit from personalized therapy in patients with PTCL.
Patients and methods
A prospective randomized controlled trial was carried out at our centre between 2010 and 2016. The trial is registered at ClinicalTrials.gov (NCT01664975). The objective was to compare the PFS, OS and response rate of GDPT with those of CHOP, and to identify genes that could be used as prognostic biomarkers in PTCL. PTCL was diagnosed by pathology through biopsies with the morphology and immunophenotype of PTCL according to the World Health Organization (WHO) classification (Jaffe et al 2001) , as well as imaging, bone marrow puncture/biopsy, physical examination and laboratory tests. After histological review and confirmation of PTCL, patients were randomly assigned to a treatment regimen.
Inclusion criteria
The inclusion criteria were: (i) Age range 14-70 years; (ii) Eastern Cooperative Oncology Group performance status 0-2; (iii) Estimated survival time > 3 months; (iv) Histologically confirmed PTCL; (v) No previous chemotherapy or radiotherapy; (vi) No chemotherapy contraindications: haemoglobin ≥ 90 g/l, neutrophil count ≥1Á5 9 10 9 /l, platelet count ≥100 9 10 9 /l, aspartate transaminase and alanine transaminase ≤2 9 upper limit of normal (ULN), serum bilirubin ≤1Á5 9 ULN, serum creatine ≤1Á5 9 ULN, serum albumin ≥30 g/l, normal serum plasminogen; (vii) At least one measurable lesion; (viii) No other serious diseases; (ix) Cardiopulmonary function was normal; (x) Pregnancy test negative; (xi) Patients could be followed up; (xii) No other previous treatments, including traditional Chinese medicine, immunotherapy, biotherapy (except anti-bone metastasis therapy) and other symptomatic treatments. Patients were excluded if they had central nervous system involvement or a prior malignancy. Patients with extranodal Natural Killer/Tcell lymphomas, nasal type were excluded. The pre-treatment staging procedures included physical examination, laboratory work-up of complete blood cell counts, b2-microglobulin, lactate dehydrogenase (LDH), liver and kidney functions, blood coagulation function, urinalysis, electrocardiography and computed tomography (CT) scans of the head, neck, thorax and abdomen. Bone marrow aspiration and biopsy were also carried out to determine whether the bone marrow was involved or not.
After staging, if the patients fulfilled the entry criteria (vide supra), they were randomized to receive either the GDPT or CHOP therapeutic regimen.
The study was carried out according to Good Clinical Practice Guidelines and the Declaration of Helsinki. This work was approved by the Local Ethics Committee of Zhengzhou University and the Scientific Council of the Faculty of Medicine. All patients were fully informed about the nature and possible toxicity of the treatment protocols and submitted written informed consent was obtained from each participating patient. PO, continued use to the termination of treatment. The starting dose of thalidomide was 50 mg and increased in 50 mg increments daily until a 200 mg maintenance dose was achieved. Aspirin at 100 mg/day, PO, was given as prophylactic anticoagulation when patients were taking thalidomide.
Treatment schedule
Each cycle was repeated 6 times every 21 days, unless there was evidence of progressive disease or significant toxicity to contraindicate continuation of treatment. Efficacy was evaluated every 2 cycles. Granulocyte colony-stimulation factor (G-CSF) was administered as support when necessary. Chemotherapy was administered according to the condition of the patients. It is recommended that dosage adjustments should be made during treatments (decrease to 80% of planned doses) in patients who develop grade 3 or 4 neutropenia or thrombocytopenia in order to maintain the timing of chemotherapy. Reasonable delays were allowed.
Biomarkers detection
With the aim of identifying biomarkers associated with antineoplastic drug sensitivity and resistance, we investigated the impact of RRM1, ERCC1, TUBB3 and TOP2A expression levels for their potential prognostic value, on the response to cisplatin, gemcitabine, vinca alkaloids and anthracycline chemotherapy in patients with PTCL, respectively. Formalinfixed and paraffin-embedded (FFPE) tissue samples from the patients, obtained from the Pathology Department of The First Affiliated Hospital of Zhengzhou University underwent mRNA quantification for these four genes. They were detected by branched DNA-liquid chip technology (bDNA-LCT) with a SurPlexTM liquid chip at a single commercial reference laboratory that provided reference values to compare with the normalized value of each gene detected. Expression was considered to be high when the detection value was ≥ the reference value, otherwise it was considered as low.
Evaluation, response criteria and toxicities
Complete Response (CR) was defined by the disappearance of all clinical, radiological and biological anomalies for at least 4 weeks. Partial Response (PR) was considered when a decrease of at least 50% of all baseline clinical and radiological anomalies was observed, without the appearance of new lesions. Progressive disease (PD) was defined as a greater than 50% increase in the sum of tumour lesions or the emergence of one or more new lesions or clinical symptoms that indicate disease progression. Stable disease (SD) was defined as any response that did not fall into the previously defined categories. Lesions were accurately measured in two dimensions by CT, magnetic resonance imaging, medical photography (skin or oral lesion), colour Doppler ultrasonography, plain X-ray or other conventional techniques. CT scanning was employed as standard imaging for the evaluation of nodal disease. Responses (CR, PR, SD and PD) were evaluated according to modified Cheson criteria (Cheson et al, 2007) . Adverse reactions were monitored by biochemical and haematological tests, urinalysis, electrocardiogram and routine physical examination. They were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3Á0 (http://ctep.cancer.gov/protoc olDevelopment/electronic_applications/docs/ctcaev3.pdf) and were assessed at each cycle from the first day of the regimen until 1 month after the termination of treatment. An intermediate evaluation was performed after two cycles of CHOP or GDPT. The final evaluation was performed 1 month after completion of the last cycle. Follow-up visits were planned every 3 months during the first year, every 6 months for the following 4 years, and then annually until relapse or the last follow-up. Physical examinations and CT scans were carried out at each evaluation and follow-up visit. Bone marrow examinations were also repeated if positive at initial diagnosis. Toxicities were evaluated after each cycle according to the WHO scale for hepatic, cardiac, renal and neurological functions (Miller et al 1981) .
End point and statistical analysis
The primary end point was to determine PFS. Assuming a 2-year PFS of 40% in the CHOP group, at least 44 patients per group were required in order to demonstrate a 25% increase of the 2-year PFS in the GDPT group (power of 75% using a one-sided test with a type I error of 0Á05). Secondary clinical objectives were to assess OS, toxicity, response rate (complete unconfirmed, complete and partial responses), and to investigate the prognostic gene factors influencing outcomes.
Response distributions and toxicity rates were compared between the two arms using the chi-square test. Two-year PFS and OS rates were compared assuming a normal distribution of the estimated survival curves using the log-rank test. PFS was calculated from the date of diagnosis to the date of progression or death from any cause. OS was calculated from the date of diagnosis to the date of death or the last follow-up. OS and PFS were estimated with standard errors and their 95% confidence intervals (CI) were estimated using the Kaplan-Meier method to account for censoring. All P values reported are two sided, and P < 0Á05 was considered to be statistically significant. Follow-up was closed for analysis in June 2016. Statistical analyses were performed with SPSS version 23 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA).
Results

Baseline characteristics of patients
Between July 2010 and June 2016, 111 patients were screened as candidates for inclusion in the study; 8 were excluded for refusing treatment (n = 1), not having PTCL (n = 1) and loss to follow-up (n = 6). Eventually, 103 eligible patientswere included with the following distribution of PTCL: PTCL-NOS in 15 cases (14Á5%), AITL in 23 cases (22Á3%), ALCL in 32 cases (31Á1%), among which 16 were ALK-positive, enteropathy-associated T-cell lymphoma (EATL) in 2 cases and others 31 cases, were randomly allocated into the two treatment groups. At diagnosis, the median age was 50 years (range, 15-70 years) and the male:female ratio was 1Á86:1. Of the cases, 48 (46Á6%) had newly diagnosed stage IV disease. Systemic B symptoms were present in 52 patients (50%) and 51 patients (50%) had elevated LDH levels. Comparative clinical presentations of each arm are listed in Table I . Patient characteristics were well balanced and no statistical differences were observed between the GDPT (52 cases) and CHOP (51 cases) groups.
Responses to therapy and survival
The ORR in the GDPT group was better than in the CHOP group (67% vs. 49%, P < 0Á05), with CR and PR rates of 52% and 15% for GDPT and 33% and 16% for CHOP (Table II) .
At a median follow-up of 20 months (range 2-72 months), the GDPT arm had a significantly better PFS and OS than the CHOP arm: 57% vs. 35% for 2-year PFS, 71% vs. 50% for 2-year OS, respectively (P < 0Á05) (Fig 1) .
Toxicity
Adverse reactions were assessed in all patients, including haematological and non-haematological toxicities. The GDPT regimen was well tolerated but produced a pattern of adverse reactions broadly similar to CHOP, with the exception of some occasionally mild thalidomide-related reactions such as somnolence, dizziness and rash. The most common adverse reactions to both regimens were haematological toxicities signifying myelosuppression, including leucopenia, thrombocytopenia and anaemia. Most non-haematological toxicities were mild and transient, including digestive tract toxicity and liver dysfunction. In the GDPT group, grade 3/4 leucopenia occurred in 20 (38%) patients with febrile neutropenia developing in 16 (31%) patients. Grade 3/4 thrombocytopenia was found in 22 (42%) patients, as well as grade 3/4 anaemia in 18 (35%) patients. Fatigue was a common manifestation among leucopenic patients. Transaminase elevation of up to more than twice the baseline value occurred in 17 (33%) patients. Seven (13%) patients complained about anesthesia, which was ascribed to the neurotoxicity of chemotherapy. Four (8%) patients suffered venous thrombosis and were treated with a thrombolytic drug without serious consequences. In the CHOP group, 2 patients (4%) suffered from grade 3 lung infection for the duration of leucopenia. At the same time, 2 patients had grade 3 heart failure and 1 patient had a grade 3 arrhythmia. No grade 4 non-haematological toxicity was detected in the study. Constipation was less frequent and reported as mild to moderate; conservative management improved this in both arms. No patient died from treatment-related infection or haemorrhage. No statistic differences were observed between the two arms in terms of grade 3/4 myelosuppression, digestive tract, hepatic, renal, cardiac or neurological toxicity. Acute toxicity was moderate, tolerable and well managed in both arms. To date, no late toxicity, including second neoplasm, has been observed. To define the safety profile of the GDPT regimen compared with the CHOP regimen, comparative toxicities are shown in Table III mRNA expression of ERCC1, RRM1, TUBB3 and TOP2A genes Evaluation of the mRNA expression levels of selected genes as potential biomarkers was performed in 43 patients, 23 in the GDPT group and 20 in the CHOP group. Other enrolled patients were excluded from this analysis because there was insufficient tissue for detection. In the GDPT group, patients were assessed for the expression of ERCC1 and RRM1. In the CHOP group, patients were assessed for the expression of TOP2A and TUBB3. The results are shown in Table IV . No significant differences were detected.
Discussion
PTCL are considered as to show high invasiveness and dismal prognosis. There is no established standard chemotherapy for PTCL, which are refractory to and have less durable remissions with anthracycline-based regimens (Lunning & Horwitz, 2013) . The generally poor outcome observed in PTCL patients emphasizes the urgent need for alternative therapy.
Encouraging results with gemcitabine have been documented; it has been shown to be one of the most active drugs when used as a single agent or in combination with conventional antineoplastic drugs against PTCL. Single-agent gemcitabine was shown to be effective and well tolerated in PTCL, and the toxicities were generally mild (grade 1-2) and manageable (Zinzani et al, 1998) . showing GDPT group has a better OS than CHOP group (P = 0Á0001). CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; GDPT, gemcitabine, cisplatin, prednisone and thalidomide. Therefore, we framed a gemcitabine-based chemotherapy protocol incorporating cisplatin, prednisone and thalidomide, which we demonstrated to have potent activity in PTCL patients.
Gemcitabine (2',2'-difluorodeoxycytidine), a pyrimidine antimetabolite, is a cytarabine congener and an attractive substitute for cytarabine with a self-potentiating mechanism, increased uptake into cells and prolonged intracellular retention in malignant cells, which can inhibit the activity of ribonucleotide reductase. This action decreases the nucleotide pool concentration inside cells, resulting in an enhanced cytotoxic effect on DNA synthesis, which, in cancerous tissue, exerts excellent antitumour activity (Dunleavy et al, 2010; Howman & Prince, 2011) . It is a cell cycle-specific agent, with lymphoma cells in S phase being sensitive to it. It has also been proven to be effective in blocking the transition process of cell proliferation from the G1 phase to the S phase (Marchi et al, 2005; Savage et al, 2011; Li et al, 2014) .
Previously, studies at our centre provided evidence of the lowest 50% inhibitory concentration value of gemcitabine among all of the chemotherapeutic agents tested and a 100% ORR was observed with gemcitabine treatment in our preliminary experiments of NK/T cell lymphoma (Li et al, 2014) . Therefore, gemcitabine can be considered to be an ideal drug for inclusion when developing new chemotherapy regimens.
The combination of gemcitabine and cisplatin has mechanistic synergy, which has been documented in several studies.
In vitro experiments have shown that gemcitabine and cisplatin have synergistic effects against various cell lines and primary cultures from patients with solid tumours. The cytotoxicity is sequence-dependent in haemopoietic tumour cells, thus gemcitabine followed by cisplatin is more cytotoxic than cisplatin followed by gemcitabine (Kroep et al, 1990) . Concerning prednisone, the valuable feature of this drug is its cytoreductive activity stemming from an ability to induce apoptosis in lymphoma (Homo-Delarche, 1984) .
In our analysis, thalidomide, which has been shown to be an active agent in multiple myeloma, also displayed activity against lymphoma. Thalidomide has been shown to have the properties of suppressing inflammation, inhibiting angiogenesis, promoting apoptosis and immunomodulation, thus exerting antitumour effects. The underlying mechanism is, at least in part, due to thalidomide-induced suppression of nuclear factor (NF)-jB and NF-jB-regulated gene products, as previously reported (Keifer et al, 2001; Wu et al, 2014; Boddicker et al, 2015; Huang et al, 2016) .
Multiple lines of evidence have shown that NF-jB plays a crucial role in lymphoma proliferation, apoptosis inhibition, chemoresistance and radioresistance (Boddicker et al, 2015) . Previously reported data suggested that NF-jB activation is a key step in T-cell lymphoma pathogenesis associated with poor OS (Odqvist et al, 2013) . Therefore, targeting the NFjB pathway has emerged as a valuable therapeutic strategy in the treatment of PTCL. A recent review (Nakanishi & Toi, 2005) details the activation of NF-jB by chemotherapeutic agents as a major factor resulting in unfavourable clinical outcomes due to chemoresistance. It has been reported that the anti-tumour effect of gemcitabine is augmented when NF-jB activity is inhibited, especially when chemoresistance to gemcitabine occurs due to the gemcitabine-induced activation of NF-jB activity (Nakanishi & Toi, 2005) .
In light of these findings, we propose that thalidomide, by suppressing the constitutive activation, as well as gemcitabine-induced activation of NF-jB activity, exerts antitumour activity and plays a synergistic role to potentiate the anti-tumour activity of gemcitabine in PTCL. This concept needs to be further validated in vitro and recapitulated in vivo to corroborate the hypothesis.
In the GDPT regimen, each component is likely to contribute to its efficacy. The mechanistic synergy without toxic overlap among these four drugs indicates that the efficacy of the whole regimen could be further increased.
Until now, there have not been any prospective clinical trials that have compared GDPT and CHOP regimens with regard to their efficacy and side effects. Thus, we initiated this randomized controlled trial and found that the GDPT group showed prolonged PFS and OS compared with the CHOP group. The ORR and CR rates in the GDPT group were also higher than those in the CHOP group.
However, our power is limited when evaluating outcomes among diverse histological subgroups, and it is difficult to determine the best therapeutic options for each of the subtypes in clinical trials because the sample sizes would be too small to draw unequivocal conclusions.
In the GDPT group, the major grade 3/4 adverse effect was myelosuppression. Grade 3/4 neutropenia and thrombocytopenia were monitored and easily managed with supportive treatment by growth factors such as G-CSF, thrombopoietin or interleukin 11, as well as infection prevention and blood component transfusions. Subsequently, blood cell counts returned to normal levels over time.
Patients with previous febrile neutropenia should be given G-CSF prophylactically to prevent a delay in the next chemotherapy cycle. Likewise, with the aim of protecting the liver, glutathione or compound glycyrrhizin injection were applied. In particular, dexrazoxane was utilized to protect the myocardium in the CHOP group. Importantly, there were no toxicities giving rise to treatment-related deaths or lifethreatening complications. Taken together, these onservations suggest that, to a large extent, the toxicity of the GDPT regimen is tolerable and acceptable, and the safety showed no inferiority to traditional CHOP regimens.
Other gemcitabine-based combination chemotherapies have also shown encouraging activity in PTCL patients. Arkenau et al (2007) (Mahadevan et al, 2013) . Taking into account the potential imbalance in selection of patients with extremely heterogenous subtypes of lymphomas and diverse patient populations, it is difficult to make formal comparisons of our results with those of other previous trials. In spite of this difficulty, the GDPT regimen in our study revealed higher PFS, OS and lower severe toxicity than those of other regimens, suggesting GDPT could be a suitable regimen superior to other treatments for patients with PTCL.
No particular gene factors have been clearly identified for PTCL. Several studies support ERCC1 and RRM1 as proven predictive parameters for non-small cell lung, ovarian or pancreatic cancers treated with cisplatin and/or gemcitabine (Bepler et al, 2006; Ulker et al, 2015) . The reasons why PTCL are not susceptible to CHOP regimen are still unexplained, but the low expression of TOP2A and high expression of TUBB3 might be a potential mechanism of chemoresistance (Ferlini et al, 2007; Bartlett et al, 2015) .
The pattern regarding the gene target of expression varied among patients and the difference did not reach statistical significance, largely due to the relatively small sample size of the patients, so the relationship between them and their sensitivity to chemotherapy is problematic.
Presently, there is no convincing evidence that these genes can be either a predictive model of PTCL response to GDPT/ CHOP regimens or general prognostic factors. As for looking for extra biomarkers, some evidence supports a definitive role for p38MAPK (also termed MAPK14) and different p38MAPK substrates as key players in the gemcitabine response, in which blockage of p38MAPK seems to be a key mechanism of resistance that still needs to be investigated in future clinical studies (Garc ıa-Cano et al, 2016 ). The precise character of these genes remains to be identified and the role of other molecules, such as p38MAPK, as putative biomarkers for the response to agents deserves further study in the management of personalized therapy in PTCL. Therefore, we look forward to the further investigation of better understanding towards the individualized treatment of selective eligibility criteria for GDPT to predict the potential response of treatment, so that PTCL patients can receive tailored regimens for better disease management.
The addition of an anti-B-cell monoclonal antibody to the traditional CHOP regimen achieved a significant tremendous leap forward in clinical outcomes. The combinations of novel drugs have brought better outcomes Dupuis et al, 2015) . It is of great interest whether a similar strategy of collaboration with targeted agents enhances the impressive effect of the GDPT regimen in the treatment of PTCL, which needs further investigation.
In conclusion, this study has identified, for the first time, a GDPT regimen that is an effective and safe protocol superior to the traditional CHOP regimen for treating patients with newly diagnosed PTCL. Thus, GDPT should be considered as the potential first-line therapy against PTCL.
